Canada Markets closed
  • S&P/TSX

    20,181.44
    -88.53 (-0.44%)
     
  • S&P 500

    4,274.04
    -31.16 (-0.72%)
     
  • DOW

    33,980.32
    -171.69 (-0.50%)
     
  • CAD/USD

    0.7740
    -0.0006 (-0.0766%)
     
  • CRUDE OIL

    87.71
    -0.40 (-0.45%)
     
  • BTC-CAD

    30,228.25
    -813.44 (-2.62%)
     
  • CMC Crypto 200

    555.78
    -17.03 (-2.97%)
     
  • GOLD FUTURES

    1,779.80
    +3.10 (+0.17%)
     
  • RUSSELL 2000

    1,987.31
    -33.22 (-1.64%)
     
  • 10-Yr Bond

    2.8930
    +0.0690 (+2.44%)
     
  • NASDAQ futures

    13,450.25
    -43.00 (-0.32%)
     
  • VOLATILITY

    19.90
    +0.21 (+1.07%)
     
  • FTSE

    7,515.75
    -20.31 (-0.27%)
     
  • NIKKEI 225

    29,222.77
    0.00 (0.00%)
     
  • CAD/EUR

    0.7599
    -0.0008 (-0.11%)
     

Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Deciphera Pharmaceuticals, Inc. DCPH have rallied 31.5% in the past three months against the industry’s decrease of 17%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Deciphera's sole marketed drug, Qinlock (ripretinib), is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). Qinlock has also been approved in Europe for the treatment of fourth-line GIST.

The company has made steady progress with Qinlock during this time frame, with the drug witnessing solid uptake so far. Qinlock contributes the majority of Deciphera’s revenues.

In first-quarter 2022, Qinlock generated sales worth $28.8 million, reflecting a sequential increase of 21.5%. Qinlock generated $23.4 million in sales in the United States and $5.4 million in sales in ex-U.S. markets.

Deciphera is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. A potential label expansion for other indications will make the drug eligible to treat a broader patient population and drive sales further in the days ahead.

In late November 2021, Deciphera entered into a corporate restructuring, whereby the company decided to streamline its commercial operations and reduce its current workforce by approximately 35% or almost 140 positions. The changes in the clinical development programs and restructuring efforts are expected to bring a significant reduction in the company’s operating expenses and extend the cash runway into 2024.

This apart, Deciphera has a diverse pipeline and is advancing multiple drug candidates in various stages of clinical development.

The company is evaluating vimseltinib in the phase III MOTION study for the treatment of tenosynovial giant-cell tumor.

A phase I study is evaluating DCC-3116 as a single agent and in combination with FDA-approved MEK inhibitors, trametinib and binimetinib as well as assotorasib, an FDA- approved KRASG12C inhibitor, for treating patients with various advanced/metastatic tumors, driven by mutations in RAS/RAF genes.

A successful development and potential approval of these candidates will be a big boost for the company.

Deciphera currently has no approved product in its portfolio other than Qinlock. All of its drug candidates, including vimseltinib and DCC-3116, are still some time away from commercialization. As a result, the company is heavily dependent on Qinlock for growth. Any regulatory setback for the drug will hurt the company’s prospects.

Deciphera Pharmaceuticals, Inc. Price

Deciphera Pharmaceuticals, Inc. Price
Deciphera Pharmaceuticals, Inc. Price

Deciphera Pharmaceuticals, Inc. price | Deciphera Pharmaceuticals, Inc. Quote

Zacks Rank & Stocks to Consider

Deciphera currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. LPTX, Aeglea BioTherapeutics, Inc. AGLE and Precision BioSciences, Inc. DTIL, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.

Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.

Aeglea BioTherapeutics’ loss per share estimates narrowed 19.4% for 2022 and 37.6% for 2023 in the past 60 days.

Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47%, on average.

Precision BioSciences’ loss per share estimates narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.

Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting